OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Catalent has announced a $175 million project to expand its manufacturing facility for large scale oral dose forms at its Winchester, Ky, site.
Catalent announced on May 19, 2022 that it has begun a $175 million project to expand its manufacturing facility in Winchester, Ky. According to a company press release, the facility, which specializes in large-scale oral dose forms, will have two new buildings and a total of 107,000 ft² added to its manufacturing footprint.
The expansion is slated to broaden the site’s highly potent material handling capabilities and containment vault, provide additional laboratory space, and add further capacity for existing turnkey operations, such as dual fill encapsulation and pan coating. These expansions follow a 2015 doubling of the site’s footprint to 190,000 ft² and a $40 million investment in 2019 that installed new equipment for stick pack dosage manufacturing, integrated packaging lines, and expanded roller compaction and fluid bed capacity.
“We are witnessing a broad increase in demand for manufacturing, and the nature of the development pipeline being strong in both oncology treatments and complex molecules, necessitates the expansion of specific capabilities in areas such as highly potent materials handling,” said Aris Gennadios, president of softgel and oral technologies, Catalent, in the press release. “Our Winchester site has a rich history in the successful commercialization of new products, and this expansion is the latest in a series of strategic investments, totaling hundreds of millions of dollars, to ensure that the current and future needs of our customers can be met.”